Why the study?
Does serial measurement of NT-proBNP predict cardiovascular death or heart failure hospitalization in patients with type 2 diabetes and recent acute coronary syndrome?
Does serial measurement of NT-proBNP predict cardiovascular death or heart failure hospitalization in patients with type 2 diabetes and recent acute coronary syndrome?
Serial monitoring of NT-proBNP in patients with type 2 diabetes and recent acute coronary syndrome is useful for identifying those at highest risk for heart failure events.
Answers are grounded in this paper and cite their sources.
May aid risk stratification in T2D post-ACS; leaves open whether serial monitoring improves outcomes or should guide therapy.
OBJECTIVE Patients with type 2 diabetes are at increased risk of developing heart failure (HF). Enhanced recognition of patients at risk for HF would help guide therapeutic decisions. RESEARCH DESIGN AND METHODS We investigated the prognostic implications of changes in N-terminal B-type natriuretic peptide (NT-proBNP) concentration in patients with type 2 diabetes and ischemic heart disease who were enrolled in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial, a phase 3b trial of alogliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor. Patients with type 2 diabetes and a recent acute coronary syndrome event were eligible. NT-proBNP was measured at baseline and 6 months. Cardiovascular (CV) death or hospitalization for HF was the end point of principal interest for this analysis. RESULTS We observed a strong graded relationship between increasing baseline and 6-month NT-proBNP concentration and the incidence of major CV events (P < 0.001). After adjusting for potential confounders, NT-proBNP at baseline was independently associated with the development of major CV events, in particular hospitalization for HF. Patients who had persistently high NT-proBNP (P < 0.001) or developed high NT-proBNP at 6 months (P < 0.001) were at a significantly higher risk for CV death/HF than those in whom NT-proBNP remained low at both time points or who had a high NT-proBNP value at baseline that subsequently declined to the low category. Absolute changes in NT-proBNP by 6 months were also strongly associated with subsequent outcomes. Treatment with a DPP-4 inhibitor did not meaningfully alter NT-proBNP concentrations (P = 0.20). CONCLUSIONS Serial monitoring of NT-proBNP in patients with type 2 diabetes and ischemic heart disease may be useful for identifying patients at highest risk for HF.
No takes yet. Share an insight, caveat, or question.
Jarolı́m et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: